Loxo Oncology Profile

155.75
USD 3.52  2.21%
1%
34%

Sale by Joshua Bilenker of 1100 shares of Loxo Oncology

Loxo Oncology insider trading alert for sale of common stock by Joshua Bilenker, President & CEO, on September 17, 2018. This event was filed by Loxo Oncology Inc with SEC on 2018-02-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Loxo Oncology Summary

Loxo Oncology (LOXO) is traded on BATS Exchange in USA. It is located in CONNECTICUT U.S.A and employs 73 people. Loxo Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 4.79 B. Loxo Oncology conducts business under Healthcare sector and is part of Biotechnology industry. This company has 30.08 M outstanding shares of which 2.41 M shares are now shorted by private and institutional investors with about 4.25 trading days to cover. Loxo Oncology currently holds about 710.23 M in cash with 244.21 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Check Loxo Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Loxo Oncology Target Price Odds Analysis

Odds Below 155.75HorizonTargetOdds Above 155.75
4.62%30 days 155.75 95.29%
Based on normal probability distribution, the odds of Loxo Oncology to move above current price in 30 days from now is over 95.29% (This Loxo Oncology probability density function shows the probability of Loxo Oncology Stock to fall within a particular range of prices over 30 days) .

Loxo Oncology Top Holders

Loxo Oncology Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Aisling Capital LlcCommon Shares3.4 M596.6 M
Vanguard Group IncCommon Shares2.4 M414.3 M
View Loxo Oncology Diagnostics

Loxo Oncology Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Loxo Oncology Key Fundamentals

Loxo Oncology Against Markets

Loxo Oncology Current Ratings

Loxo Oncology 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
31 
Equity ratings for Loxo Oncology are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 73 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Loxo Oncology SEC Filings
Loxo Oncology SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameLoxo Oncology
President CEO, DirectorJoshua BilenkerView All
Thematic Classification
Currently Active Investing Idea
Cancer Fighters
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCONNECTICUT U.S.A
Business Address281 Tresser Boulevard
ExchangeBATS Exchange
CIK Number0001581720
CUSIP548862101
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.loxooncology.com
Phone203 653 3880
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterMarch 31, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestJuly 13, 2018

Loxo Oncology Directors

Loxo Oncology Corporate Directors

James Barrett Independent Director
Timothy Mayleben Independent Director
Avraham Naider Independent Director
Please see also Stocks Correlation. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Search macroaxis.com